Final analysis of a randomized phase II trial of bevacizumab and gemcitabine plus cetuximab or erlotinib in patients with advanced pancreatic cancer Hedy.
Disclosures
April 9, 2011 Diagnostic Molecular Pathology Update Christopher D. Gocke, M.D. Associate Professor of Pathology & Oncology Johns Hopkins Medical Institutions.
EGFR Inhibitors in Colorectal Cancer John L. Marshall, MD Lombardi Comprehensive Cancer Center.
Jennie Bell CMGS/ACC Spring meeting 14 th April 2010.
Advances in the Management of Lung Cancer: Highlights from the 2014 ASCO Annual Meeting
